کتابخانه مرکزی دانشگاه صنعتی شریف
    • [نمايش بزرگتر]
    • [نمايش کوچکتر]
  • صفحه 
     از  0
  • [صفحه قبل]
  • [صفحه بعد]
  • [نمایش تمام صفحه]
  • [بستن]
 
Cellulite : pathophysiology and treatment [electronic resource]

اطلاعات کتابشناختی

Cellulite : pathophysiology and treatment [electronic resource]
Author :  
Publisher :   Taylor & Francis,
Pub. Year  :   2006
Subjects :   Cellulite -- Pathophysiology. Obesity -- Pathophysiology. Adipose tissues --...
Call Number :   ‭RC 628 .C42 2006

جستجو در محتوا

ترتيب

فهرست مطالب

  • Cover Page (1)
  • BASIC AND CLINICAL DERMATOLOGY (3)
  • Title Page (6)
  • ISBN 0824729854 (7)
  • Series Introduction (8)
  • Foreword (10)
  • Preface (12)
    • WHY CELLULITE IS A CONCERN FOR US (14)
    • REFERENCES (16)
  • Contents (18)
  • Contributors (24)
  • 1 Social Impact of Cellulite and Its Impact on Quality of Life (26)
    • INTRODUCTION (26)
    • ASPECTS OF CELLULITE RELATED TO QOL (27)
    • CONCLUSIONS (29)
    • REFERENCES (30)
  • 2 Definition, Clinical Aspects, Associated Conditions, and Differential Diagnosis (32)
    • DEFINITION (32)
    • NOMENCLATURE (34)
    • CLINICAL ASPECTS (34)
      • CLASSIFICATION (36)
      • CLINICAL APPROACH (36)
      • AGGRAVATING FACTORS (41)
      • COMPLEMENTARY EXAMINATIONS (44)
    • DIFFERENTIAL DIAGNOSIS (46)
    • REFERENCES (49)
    • APPENDIX (52)
  • 3 Anatomy of Cellulite and the Interstitial Matrix (54)
    • INTRODUCTION (54)
    • CELLULITE (54)
      • LYMPHEDEMA (55)
      • LIPEDEMA AND LIPOLYMPHEDEMA (56)
      • DERCUM SYNDROME (56)
      • ‘‘BIG LEG’’ (57)
    • INTERSTITIAL MATRIX (57)
    • REFERENCES (63)
  • 4 Pathophysiology of Cellulite (66)
    • WHAT IS CELLULITE? (66)
    • DEFINITION (66)
      • HOW TO DEFINE THE UNAESTHETIC SIDE OF CELLULITE (68)
    • CLASSIFICATION (68)
    • EVOLUTION (72)
      • WHEN DOES CELLULITE BECOME EVIDENT? (72)
      • WHAT IS THE RELATIONSHIP BETWEEN CELLULITE AND OBESITY? (72)
      • PREDISPOSING FACTORS (73)
      • TRIGGERING FACTORS (74)
    • LIPEDEMA AND LIPOLYMPHEDEMA: PATHOLOPHYSIOLOGIC HYPOTHESES (75)
      • LYMPH (77)
      • THE LYMPHATIC SYSTEM (78)
      • LYMPHATIC CIRCULATION (78)
      • VARIATIONS IN LYMPH (79)
      • THE FIBROBLAST AND THE INTERSTITIAL MATRIX (79)
      • THE ADIPOCYTE (80)
      • HYPODERMIS AND FAT METABOLISM (81)
    • LIPODYSTROPHY (82)
    • THE LYMPHOADIPOSE SYSTEM (83)
    • VENOUS–LYMPHATIC STASIS (86)
    • HOW CELLULITE DEVELOPS (87)
    • MANIFESTATIONS OF CELLULITE (87)
    • CLINICAL CLASSIFICATION (88)
    • WHY CELLULITE IS A CONCERN (88)
    • LIPOSCLEROSIS AND LOCALIZED ADIPOSITY (88)
      • ABOUT GLYCOSAMINOGLYCANS (92)
    • ETIOPATHOGENIC FACTORS (93)
    • THE TERM ‘‘CELLULITE’’ (95)
    • REFERENCES (97)
  • 5 Diagnosis (100)
    • PATIENT HISTORY (100)
    • CLINICAL EXAMINATION (100)
      • INSPECTION (103)
      • PALPATION (103)
      • POSTURE ASSESSMENT (104)
      • PHLEBOLYMPHOLOGIC ASSESSMENT (104)
      • ADIPOSE TISSUE ECHOGRAPHY (104)
    • LABORATORY INVESTIGATIONS (105)
    • ROM TEST (106)
    • PRIMARY INSTRUMENT EXAMINATIONS (107)
      • VIDEOCAPILLAROSCOPY (107)
      • REFLECTED LIGHT PHOTOPLETHYSMOGRAPHY (109)
      • ECHOGRAPHY/ULTRASOUND (109)
      • DYNAMIC FOOT STUDY (111)
    • SECONDARY INSTRUMENT EXAMINATIONS (111)
      • DOPPLER LASER (111)
      • DOPPLER (111)
      • ECHODOPPLER (112)
      • THERMOGRAPHY (113)
    • PHOTOGRAPHY (113)
    • DIAGNOSIS (113)
      • DISTRIBUTION (114)
        • Generalized Cellulite (114)
        • Localized Cellulite (115)
      • CONSISTENCY (116)
        • Hard Cellulite (116)
        • Soft Cellulite (117)
        • Edematous Cellulite (118)
        • Mixed Cellulite (119)
      • EVOLUTION (119)
    • THERAPEUTIC STRATEGY (120)
    • MEDICAL HISTORY (120)
    • REFERENCES (122)
    • APPENDIX (123)
  • 6 Cellulite Characterization by High-Frequency Ultrasound and High-Resolution Magnetic Resonance Imaging (130)
    • INTRODUCTION (130)
    • MATERIALS AND METHODS (130)
      • SUBJECTS (130)
      • US IMAGING (131)
      • MR IMAGING (131)
      • MR SPECTROSCOPY (132)
      • STATISTICS (132)
    • RESULTS (133)
      • SKIN THICKNESS (133)
      • ADIPOSE THICKNESS (133)
      • 3-D ARCHITECTURE OF ADIPOSE TISSUE (134)
      • LIPID COMPONENTS AND WATER FRACTION IN ADIPOSE TISSUE (137)
    • DISCUSSION (137)
    • REFERENCES (139)
  • 7 Clinical–Therapeutic Classification: BIMED–TCD (140)
    • INTRODUCTION (140)
    • BINAZZI’S CLASSIFICATION (140)
    • CURRI’S CLASSIFICATION (141)
    • BARTOLETTI’S CLASSIFICATION (141)
    • BIMED CLASSIFICATION (142)
    • BIMED–TCD CLASSIFICATION (152)
      • T FACTOR: AS A THERMOGRAPHIC OUTLINE OF ALBERGATI/ CURRI (11) ON A SCALE OF 0 TO 25 (152)
      • THE C FACTOR (152)
      • TCD CODE (154)
    • PATHOPHYSIOLOGICAL CLASSIFICATION AND PROTOCOLS OF BIMED–TCD (155)
    • EDEMATOUS CELLULITE (156)
      • THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days) (158)
    • ADIPOSE CELLULITE (159)
      • THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days) (160)
    • INTERSTITIAL CELLULITE (LIPEDEMA) (160)
      • THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days) (161)
    • FIBROUS CELLULITE (162)
      • THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days) (163)
    • SUMMARY (164)
    • REFERENCES (165)
  • 8 Medical Treatment of Cellulite (168)
    • INTRODUCTION (168)
      • G. BILOBA EXTRACTS (169)
      • PURIFIED ASIATIC CENTELLA: TRITERPENES AS PHYTOSOMES (169)
      • MELILLOTUS OFFICINALIS EXTRACT (169)
      • FUCUS VESCICULOSUS EXTRACT (170)
    • ABSTRACTS OF STUDIES IN CELLASENE (171)
    • NEW RESEARCH ABOUT THE USE OF CELLASENE OR CELLULASE GOLD (172)
    • REFERENCES (178)
  • 9 Theory and Working Principles of Beautytek1 in Cosmetic Medicine (180)
  • 10 Topical Management of Cellulite (184)
    • INTRODUCTION (184)
    • DEFINITION AND NATURE OF CELLULITE (185)
    • PATHOPHYSIOLOGIC MECHANISMS OF CELLULITE FORMATION (185)
    • TOPICAL MANAGEMENT (186)
      • AGENTS THAT INCREASE MICROVASCULAR FLOW (187)
      • AGENTS THAT REDUCE LIPOGENESIS AND PROMOTE LIPOLYSIS (189)
      • AGENTS THAT RESTORE THE NORMAL STRUCTURE OF THE DERMAL AND SUBCUTANEOUS TISSUE (190)
      • AGENTS THAT PREVENT OR DESTROY FREE-RADICAL FORMATION (190)
      • COMBINATION AGENTS (191)
      • EXTERNAL AIDS TO TOPICAL THERAPY (191)
      • ADVERSE EVENTS (193)
    • CONCLUSION (193)
    • REFERENCES (194)
  • 11 The Role of Endermologie in Treatment of Cellulite (196)
    • INTRODUCTION (196)
    • ANATOMY AND PHYSIOLOGY (198)
      • EPIDERMIS (198)
      • DERMIS (198)
      • LIPODERMA (199)
        • The Connective Tissue (199)
        • The Interstitial Matrix (201)
    • ADIPOSE TISSUE AND LIPODERMA (201)
    • THE SUPERFICIAL FASCIA (202)
    • MASSAGE (203)
    • MANUAL LYMPHATIC DRAINAGE (203)
    • THE TECHNIQUE ‘‘ENDERMOLOGIE" (203)
      • HISTORY AND PRINCIPLES (203)
      • What Is Endermologie–Cellu M6? (203)
      • MECHANISM OF ACTION (204)
      • Treatment Phase (206)
    • INDICATIONS (206)
      • PHLEBOLYMPHOLOGY (206)
      • PLASTIC AND AESTHETIC SURGERY (206)
      • CELLULITIC SYNDROMES Cellulite and Endermologie (206)
    • METHOD (207)
    • CONCLUSIONS (210)
    • REFERENCES (211)
  • 12 The Use of TriActive in the Treatment of Cellulite (214)
    • MECHANISM (214)
    • REVIEW OF CELLULITE (214)
    • PARAMETERS (214)
    • INITIAL STUDIES (215)
    • OTHER USES (216)
    • CONTRAINDICATIONS (216)
    • PROTOCOL (216)
  • 13 Carboxytherapy (222)
    • INTRODUCTION (222)
    • INDICATIONS (223)
    • TREATMENT METHOD (226)
      • CONTRAINDICATIONS (228)
      • SIDE EFFECTS (230)
      • PROTOCOL FOR CARBOXYTHERAPY IN CELLULITE (230)
    • CONCLUSIONS (232)
    • REFERENCES (234)
  • 14 Surgical Treatment (236)
    • A: Lipoplasty, Vibro-Assisted Liposuction, Lipofilling, and Ultrasonic Hydroliposuction (236)
      • LIPOPLASTY (236)
      • HISTORICAL BACKGROUND (237)
    • B: VASER (245)
      • DEFINITION (247)
      • FAT TISSUE VASCULARIZATION (248)
        • AREOLAR FAT (248)
        • DEEP FAT (248)
      • PATIENT SELECTION (248)
        • PRESURGICAL VISIT (249)
        • DETAILED PHYSICAL EXAMINATION (252)
      • PRESCRIPTIONS (253)
      • POSTOPERATIVE SCHEME & (254)
      • CONCLUSION (255)
    • C: Vibro-Assisted Liposuction (256)
      • INTRODUCTION (256)
      • LIPOPLASTY (257)
      • LIPOLYMPHOSUCTION (257)
      • THE VIBRO-ASSISTED METHOD (257)
    • D: Lipofilling (259)
      • LIFTING (261)
      • LIPOSHIFTING (262)
    • E: Ultrasonic Hydrolipoclasis (External Ultrasound) (264)
      • CAVITATION (267)
      • BIOLOGICAL EFFECTS (267)
      • TECHNIQUE (269)
        • PATIENT PREPARATION (269)
        • SOLUTION PREPARATION (269)
        • INFILTRATION (269)
        • ULTRASOUND APPLICATION (270)
        • FREQUENCY OF TREATMENT (271)
        • SIDE EFFECTS (271)
    • REFERENCES (273)
  • 15 Subcision (276)
    • INTRODUCTION (276)
    • INDICATIONS AND MECHANISMS OF ACTION (276)
    • CONTRAINDICATIONS FOR SUBCISION (279)
    • PREOPERATIVE CONSULTATION (279)
    • SURGICAL TECHNIQUE (279)
    • THE POSTOPERATIVE PERIOD (282)
    • COMPLICATIONS (282)
    • CONCLUSIONS (285)
    • REFERENCES (287)
  • 16 Mesotherapy in the Treatment of Cellulite (288)
    • A BRIEF HISTORY (288)
    • THE CONCEPT (288)
    • ACTION MECHANISM OF MESOTHERAPY (289)
      • PISTORIAN REFLEX THEORY (289)
      • BICHERON’S MICROCIRCULATORY THEORY (289)
      • MESODERMIC THEORY (290)
      • THIRD CIRCULATION THEORY (290)
    • BENEFITS AND ADVANTAGES OF THE METHOD (290)
    • MATERIALS AND TECHNIQUES (291)
      • SKIN ANTISEPSIS (291)
      • MANUAL TECHNIQUES (291)
    • GENERAL INDICATIONS FOR MESOTHERAPY (292)
    • MESOTHERAPY IN CELLULITE (292)
      • SIDE EFFECTS (292)
      • COMPLICATIONS (8–45) (294)
    • USES FOR MESOTHERAPY (295)
      • FAT LOSS (295)
      • CELLULITE REDUCTION (295)
      • FACE AND NECK REJUVENATION WITH MESOLIFT (295)
      • FOUR ESSENTIAL QUESTIONS THAT EXPLAIN THE MESOTHERAPY TECHNIQUE (296)
    • WHAT IS MESOTHERAPY? (296)
    • WHY ARE DRUGS INJECTED INTO THE SKIN? (296)
    • WHAT DRUGS ARE USED? (296)
      • CRITERIA FOR USE OF MEDICINES (297)
    • WHICH DRUGS SHOULD BE USED AND HOW SHOULD THEY BE ADMINISTERED? (297)
      • CONCERNS REGARDING THE CHOICE OF DRUG COMBINATIONS (297)
      • SUBSTANCE USED (297)
      • ADMINISTRATION (299)
      • RECEPTORS (299)
      • METHOD OF APPLICATION (299)
      • PROCEDURE (299)
      • MATERIALS REQUIRED (19) (300)
    • DRUGS AND PRODUCTS USED IN MESOTHERAPY (302)
      • DISINFECTANTS (302)
      • AESCULUS (23) (302)
      • CONJOCTYL (SALICYLATE OF MONOMETILSILANOTRIOL) (24) (302)
      • CHOFITOL: (EXTRACT OF ALCACHOFA–C SCOLYMUS) (25) (303)
      • MELILOTUS-RUTOSIDO (26) (303)
      • PROCAINE (304)
      • BUFLOMEDIL (304)
      • CAFFEINE (304)
      • PHENTOLAMINE (305)
      • GINKGO BILOBA (305)
      • MESOGLYCANS (305)
      • PENTOXIFYLLINE (305)
      • THEOPHYLLINE (305)
      • TRIAC (306)
      • YOHIMBINE (306)
    • NO-NEEDLE MESOTHERAPY (307)
    • CONCLUSION (308)
      • DIFFERENCES BETWEEN THE RESULTS OF MESOTHERAPY AND LIPOSCULPTURE (308)
    • REFERENCES (309)
  • 17 Manual Lymphatic Drainage (312)
    • REFERENCES (315)
  • 18 The Role of Dermoelectroporation (316)
    • INTRODUCTION (316)
    • TRANSDERM METHOD (317)
    • CHARACTERISTIC FEATURES (317)
    • POSSIBLE USES (318)
    • DERMOELECTROPORATION TREATMENT (318)
    • CLINICAL STUDY (319)
    • CONCLUSIONS (322)
    • ACKNOWLEDGMENT (322)
    • REFERENCES (323)
  • 19 Lipodissolve for Body Sculpting (326)
    • INTRODUCTION (326)
    • PHOSPHATIDYLCHOLINE (PC) (327)
    • DEOXYCHOLATE (DEOXYCHOLIC ACID) (330)
    • AVAILABILITY OF LIPOSTABIL IN THE UNITED STATES AND CANADA (331)
      • LIPOSTABIL1 IN THE UNITED STATES AND CANADA (331)
    • CONTRAINDICATIONS FOR LIPODISSOLVE INJECTIONS (332)
    • SIDE EFFECTS OF LIPODISSOLVE INJECTIONS (332)
      • LOCAL SIDE EFFECTS (IN THE INJECTED AREA) (332)
      • SYSTEMIC SIDE EFFECTS (CHOLINERGIC) (332)
    • DOSAGES AND TECHNIQUES FOR LIPODISSOLVE INJECTIONS (334)
    • GENERAL CONSIDERATIONS FOR LIPODISSOLVE INJECTIONS (334)
    • LIPODISSOLVE FORMULAE FOR FAT PAD DISSOLUTION (335)
      • LIDOCAINE (336)
      • HOW TO MAKE LIPODISSOLVE SOLUTION IN THE OFFICE (337)
    • PROCEDURE FOR INJECTING LIPODISSOLVE INTO (337)
      • FATTY PADS (337)
      • TYPICAL INJECTION PATTERN USING A 5ML SYRINGE (FIG. 3) (337)
      • LIPODISSOLVE FOR INFRAORBITAL FAT PADS (RITTES’ TECHNIQUE) (338)
    • CLINICAL EXAMPLES OF LIPODISSOLVE THERAPY (338)
    • LIPODISSOLVE SUMMARY: SIMPLE INJECTIONS FOR FAT REDUCTION (338)
    • REFERENCES (347)
  • Index (348)
Loading...